Gladius Capital Management LP Makes New $30,000 Investment in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Gladius Capital Management LP acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,605 shares of the company’s stock, valued at approximately $30,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRVI. Bank of New York Mellon Corp lifted its holdings in shares of Maravai LifeSciences by 1.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 515,123 shares of the company’s stock worth $5,151,000 after purchasing an additional 9,592 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Maravai LifeSciences by 43.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,174 shares of the company’s stock valued at $242,000 after purchasing an additional 7,264 shares during the period. Advisor Partners II LLC bought a new position in Maravai LifeSciences in the 3rd quarter worth about $115,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after buying an additional 1,662 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Maravai LifeSciences by 43.3% during the third quarter. Jennison Associates LLC now owns 2,547,753 shares of the company’s stock worth $25,478,000 after buying an additional 769,362 shares during the period. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Stock Up 11.2 %

NASDAQ MRVI traded up $0.99 on Thursday, reaching $9.86. The stock had a trading volume of 5,157,152 shares, compared to its average volume of 2,509,449. Maravai LifeSciences Holdings, Inc. has a 1 year low of $4.52 and a 1 year high of $16.62. The company has a current ratio of 8.00, a quick ratio of 7.41 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $2.48 billion, a price-to-earnings ratio of -10.47 and a beta of 0.03. The business has a 50 day moving average price of $8.09 and a 200 day moving average price of $6.73.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. On average, analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.15 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Stifel Nicolaus reduced their price target on Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Robert W. Baird raised their target price on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Thursday. Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research note on Wednesday, April 10th. They set a “buy” rating and a $15.00 price objective on the stock. Finally, Royal Bank of Canada increased their price target on Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.44.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.